Business
NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
(TheNewswire)     Vancouver, British Columbia – March 11, 2026 – Th...
About this update from Neurothera Labs Inc.
[{"type":"text","content":"NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease\n(TheNewswire)\n\n\n\n \n\n \n\n\nVancouver, British Columbia – March 11, 2026 –\nTheNewswire – NeuroThera\nLabs Inc. (TSXV: NTLX) (the \"Company\" or\n\"NeuroThera\"), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), has advanced its collaboration with Clearmind Medicine Inc.\nwith the publication of an international patent application under the\nPatent Cooperation Treaty (PCT) for a novel combination therapy aimed\nat treating weight loss and metabolic dysfunction-associated steatotic\nliver disease (MASLD, formerly known as fatty liver disease).\n\n\n \n\n\nThe patent publication highlights the potential of a\n 5-methoxy-2-aminoindane (MEAI)- Palmitoylethanolamide (PEA) combination to offer a safe,\nnon-hallucinogenic neuroplastogen treatment for two major global\nhealth challenges: obesity, affecting over 890\nmillion adults worldwide, and MASLD,\nimpacting approximately 30% of the global adult\npopulation. Moreover, due to the\npresumed mechanism of action of the combination, this therapeutic\noption may offer a safer, easier and more cost effective option than\nGLP-1s agonists for obesity and MASLD.\n\n\n \n\n\nBy combining Clearmind’s MEAI platform with\nNeuroThera’s PEA, the companies wish to address the escalating\ndemand for effective, tolerable and safe treatments in the obesity and\nliver health space. This comes at a time when the global weight loss\ndrugs market is experiencing rapid growth, which was valued at\napproximately $37 billion in 2025 and\nis forecasted to reach $226 billion by 2035, driven by increasing awareness of obesity as a chronic\ndisease and the need for innovative alternatives to GLP-1\nagonists.\n\n\n \n\n\nAbout NeuroThera Labs Inc.\n\n\nNeuroThera Labs Inc. (TSXV: NTLX) is a\nclinical-stage pharmaceutical company focused on developing novel\ntherapeutics for central nervous system disorders and other\nunderserved health conditions through collaborations and innovative combinations.\n\n\nAbout Clearmind Medicine Inc.\n\n\nClearmind is a clinical-stage neuroplastogens pharmaceutical biotech\ncompany focused on the dis...